No Data
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $21
Lexeo Therapeutics Shares Are Trading Lower. The Company Announced Interim Results From Its Phase 1/2 Study of LX1001.
Lexeo Therapeutics Announced Interim Results From Phase 1/2 Study Of LX1001 For Alzheimer's Disease, Showing LX1001 Led To Dose-dependent Increases In APOE2 Protein Expression And Improvements In Associated Tau Biomarkers
Express News | Lexeo Therapeutics - Sees Further Lx1001 Development Plans in 2025
Express News | Lexeo Therapeutics Inc - Lx1001 Well Tolerated With No Reports of Aria
Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $23
No Data
No Data